

Cathrin Ritter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/970381/publications.pdf>

Version: 2024-02-01

13
papers

482
citations

840776

11
h-index

1125743

13
g-index

13
all docs

13
docs citations

13
times ranked

975
citing authors

#	ARTICLE	IF	CITATIONS
1	Merkel cell carcinoma-derived exosome-shuttle miR-375 induces fibroblast polarization by inhibition of RBPJ and p53. <i>Oncogene</i> , 2021, 40, 980-996.	5.9	32
2	Classical and Variant Merkel Cell Carcinoma Cell Lines Display Different Degrees of Neuroendocrine Differentiation and Epithelial-Mesenchymal Transition. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1675-1686.e4.	0.7	13
3	MCPyV Large T Antigen-Induced Atonal Homolog 1 Is a Lineage-Dependency Oncogene in Merkel Cell Carcinoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 56-65.e3.	0.7	35
4	Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2257-2267.	7.0	39
5	Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 4266-4281.	8.2	27
6	MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells. <i>Cancer Immunology Research</i> , 2019, 7, 1472-1484.	3.4	39
7	Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration. <i>International Journal of Cancer</i> , 2019, 145, 1020-1032.	5.1	44
8	Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 341-351.	4.2	88
9	Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5873-5882.	7.0	45
10	T cell receptor repertoire usage in cancer as a surrogate marker for immune responses. <i>Seminars in Immunopathology</i> , 2017, 39, 255-268.	6.1	65
11	Update on the clinical use of kinase inhibitors in melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 887-893.	0.8	9
12	Reversal of epigenetic silencing of MHC class I chain-related protein A and B improves immune recognition of Merkel cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 21678.	3.3	43
13	STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFN- γ Therapy in Stage III Melanoma Patients. <i>Frontiers in Medicine</i> , 2014, 1, 47.	2.6	3